6.66
0.31 (4.85%)
| Previous Close | 6.35 |
| Open | 6.46 |
| Volume | 31,048 |
| Avg. Volume (3M) | 34,429 |
| Market Cap | 91,804,544 |
| Price / Earnings (TTM) | 20.18 |
| Price / Earnings (Forward) | 22.88 |
| Price / Sales | 1.60 |
| Price / Book | 23.29 |
| 52 Weeks Range | |
| Earnings Date | 11 Dec 2025 |
| Profit Margin | 8.26% |
| Operating Margin (TTM) | -13.87% |
| Diluted EPS (TTM) | 0.330 |
| Quarterly Revenue Growth (YOY) | -11.80% |
| Total Debt/Equity (MRQ) | 167.68% |
| Current Ratio (MRQ) | 0.940 |
| Operating Cash Flow (TTM) | 7.39 M |
| Levered Free Cash Flow (TTM) | 5.40 M |
| Return on Assets (TTM) | 10.36% |
| Return on Equity (TTM) | 503.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Champions Oncology, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.0 |
| Average | 0.50 |
|
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 25.95% |
| % Held by Institutions | 49.51% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Battery Management Corp. | 30 Jun 2025 | 2,421,673 |
| Nea Management Company, Llc | 30 Jun 2025 | 1,713,720 |
| Tocqueville Asset Management L.P. | 30 Jun 2025 | 399,882 |
| Hightower Advisors, Llc | 30 Jun 2025 | 35,158 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Sep 2025 | Announcement | CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million |
| 15 Sep 2025 | Announcement | Champions Oncology Reports Record Quarterly Revenue of $14.0 Million |
| 10 Sep 2025 | Announcement | Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025 |
| 23 Jul 2025 | Announcement | Champions Oncology Reports Record Annual Revenue of $57 Million |
| 21 Jul 2025 | Announcement | Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025 |
| 18 Jul 2025 | Announcement | Champions Oncology Announces Appointment of New CEO |
| 08 Jul 2025 | Announcement | Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |